Advances in neuroimaging in frontotemporal dementia
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Frontotemporal dementia (FTD) is a clinically and neuroanatomically heterogeneous neurodegenerative disorder with multiple underlying genetic and pathological causes. Whilst initial neuroimaging studies highlighted the presence of frontal and temporal lobe atrophy or hypometabolism as the unifying feature in patients with FTD, more detailed studies have revealed diverse patterns across individuals, with variable frontal or temporal predominance, differing degrees of asymmetry, and the involvement of other cortical areas including the insula and cingulate, as well as subcortical structures such as the basal ganglia and thalamus. Recent advances in novel imaging modalities including diffusion tensor imaging, resting‐state functional magnetic resonance imaging and molecular positron emission tomography imaging allow the possibility of investigating alterations in structural and functional connectivity and the visualisation of pathological protein deposition. This review will cover the major imaging modalities currently used in research and clinical practice, focusing on the key insights they have provided into FTD, including the onset and evolution of pathological changes and also importantly their utility as biomarkers for disease detection and staging, differential diagnosis and measurement of disease progression. Validating neuroimaging biomarkers that are able to accomplish these tasks will be crucial for the ultimate goal of powering upcoming clinical trials by correctly stratifying patient enrolment and providing sensitive markers for evaluating the effects and efficacy of disease‐modifying therapies. image This review describes the key insights provided by research into the major neuroimaging modalities currently used in research and clinical practice, including what they tell us about the onset and evolution of FTD and how they may be used as biomarkers for disease detection and staging, differential diagnosis and measurement of disease progression. This article is part of the Frontotemporal Dementia special issue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Neurodegenerative Diseases Target Large-Scale Human Brain Networks
Seeley, W. W., Crawford, R. K., Zhou, J., Miller, B. L., & Greicius, M. D. (2009) · Neuron · doi:10.1016/j.neuron.2009.03.024 · Cited by 2,350
Mackenzie, I. R. A., Neumann, M., Bigio, E. H., Cairns, N. J., Alafuzoff, I., Kril, J., Kovacs, G. G., Ghetti, B., Halliday, G., Holm, I. E., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0612-2 · Cited by 1,012
A hitchhiker's guide to diffusion tensor imaging
Soares, J. M., Marques, P., Alves, V., & Sousa, N. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00031 · Cited by 893
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · cited 1×
“This has shown value in the detection of amyloid-relating imaging abnormalities as a response to anti-amyloid immunotherapy trials in AD (Sperling et al. 2011).”
BackgroundMosconi, L., Tsui, W. H., Herholz, K., Pupi, A., Drzezga, A., Lucignani, G., Reiman, E. M., Holthoff, V., Kalbe, E., Sorbi, S., et al. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045385 · Cited by 726 · cited 1×
“Involvement of the hippocampus, anterior cingulate, basal ganglia, anterior insula and thalamus have been less consistently reported, most likely because of variability in techniques, underlying pathology and disease severity between studies (Schroeter et al. 2007; Mosconi et al. 2008).”
BackgroundEarly clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807
Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651
Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review
Seelaar, H., Rohrer, J. D., Pijnenburg, Y. A. L., Fox, N. C., & van Swieten, J. C. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.212225 · Cited by 609 · cited 1×
“Frontotemporal dementia (FTD) is a clinically, genetically and pathologically heterogeneous neurodegenerative disorder (Seelaar et al. 2011) and a common cause of early onset dementia (Onyike and Diehl-Schmid 2013).”
BackgroundSelf-citationFDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease
Foster, N. L., Heidebrink, J. L., Clark, C. M., Jagust, W. J., Arnold, S. E., Barbas, N. R., DeCarli, C. S., Scott Turner, R., Koeppe, R. A., Higdon, R., et al. (2007) · Brain · doi:10.1093/brain/awm177 · Cited by 608
[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605 · cited 2×
“A novel benzimidazole–pyrimidine derivative, (18)F-T807 (now known as (18)F-AV-1451) has been described (Xia et al. 2013; Chien et al. 2014), which exhibits greater than 25fold selectivity for tau over Ab and preliminary findings from human trials have reported cortical retention matching known distribution of tau pat…”
Background
Cited by
Imaging and fluid biomarkers in frontotemporal dementia
Meeter, L. H., Kaat, L. D., Rohrer, J. D., & van Swieten, J. C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.75 · Cited by 210
Self-citationReyes, P., Ortega-Merchan, M. P., Rueda, A., Uriza, F., Santamaria-García, H., Rojas-Serrano, N., Rodriguez-Santos, J., Velasco-Leon, M. C., Rodriguez-Parra, J. D., Mora-Diaz, D. E., et al. (2018) · Behavioural Neurology · doi:10.1155/2018/9684129 · Cited by 52
Saba, V., Premi, E., Cristillo, V., Gazzina, S., Palluzzi, F., Zanetti, O., Gasparotti, R., Padovani, A., Borroni, B., & Grassi, M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00211 · Cited by 33
Clayton, E. L., Mancuso, R., Nielsen, T. T., Mizielinska, S., Holmes, H., Powell, N., Norona, F., Overgaard Larsen, J., Milioto, C., Wilson, K. M., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx003 · Cited by 32
Johnen, A., Reul, S., Wiendl, H., Meuth, S. G., & Duning, T. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.04.002 · Cited by 29
“This interpretation also fits well with the neuroanatomical evidence that semantic knowledge is predominantly subserved by areas in the anterior (ventral) temporal lobe, the key target of neurodegeneration in svPPA [40].”
Background
Metadata
- Authors
- Gordon, E., Rohrer, J. D., & Fox, N. C.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2016-08
- Volume
- 138
- Issue
- S1
- Pages
- 193-210
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2510156330
- Cited by
- 94
- References
- 39
- FWCI
- 8.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in neuroimaging in frontotemporal dementia. https://app.cochat.ai/papers/10.1111/jnc.13656
- The paper
- Gordon, E., Rohrer, J. D., & Fox, N. C. (2016). Advances in neuroimaging in frontotemporal dementia. Journal of Neurochemistry. https://doi.org/10.1111/jnc.13656
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.